Bfsg LLC Has $4.19 Million Stock Position in ResMed Inc. (NYSE:RMD)

Bfsg LLC lowered its holdings in shares of ResMed Inc. (NYSE:RMD) by 1.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 17,167 shares of the medical equipment provider’s stock after selling 166 shares during the period. Bfsg LLC’s holdings in ResMed were worth $4,191,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Indiana Trust & Investment Management Co acquired a new stake in ResMed during the 3rd quarter worth approximately $98,000. Vontobel Holding Ltd. increased its position in ResMed by 8.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 3,662 shares of the medical equipment provider’s stock worth $894,000 after buying an additional 288 shares during the period. Birch Capital Management LLC lifted its holdings in shares of ResMed by 7.6% during the third quarter. Birch Capital Management LLC now owns 29,275 shares of the medical equipment provider’s stock worth $7,147,000 after buying an additional 2,080 shares in the last quarter. Creative Planning boosted its position in shares of ResMed by 15.4% in the third quarter. Creative Planning now owns 28,021 shares of the medical equipment provider’s stock valued at $6,840,000 after acquiring an additional 3,739 shares during the period. Finally, CHICAGO TRUST Co NA acquired a new position in shares of ResMed in the third quarter valued at about $234,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on RMD shares. Oppenheimer lowered shares of ResMed from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 25th. Baird R W raised ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. KeyCorp lifted their price objective on ResMed from $238.00 to $251.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Wolfe Research reissued an “underperform” rating and set a $180.00 target price on shares of ResMed in a report on Wednesday, September 18th. Finally, StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $218.18.

Insider Activity

In related news, insider Justin Leong sold 48,000 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $217.07, for a total value of $10,419,360.00. Following the transaction, the insider now directly owns 18,741 shares in the company, valued at $4,068,108.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $214.25, for a total transaction of $3,145,832.75. Following the completion of the sale, the chief executive officer now directly owns 440,799 shares of the company’s stock, valued at approximately $94,441,185.75. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Justin Leong sold 48,000 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $217.07, for a total value of $10,419,360.00. Following the completion of the sale, the insider now directly owns 18,741 shares of the company’s stock, valued at approximately $4,068,108.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 123,874 shares of company stock worth $28,151,142 over the last quarter. 1.21% of the stock is currently owned by corporate insiders.

ResMed Stock Down 0.3 %

ResMed stock opened at $238.46 on Thursday. The company has a market capitalization of $35.03 billion, a PE ratio of 36.63, a PEG ratio of 2.14 and a beta of 0.69. ResMed Inc. has a 12-month low of $132.24 and a 12-month high of $255.18. The firm’s fifty day moving average is $237.80 and its 200 day moving average is $215.36. The company has a quick ratio of 1.69, a current ratio of 2.59 and a debt-to-equity ratio of 0.14.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.05. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.22 billion. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.60 earnings per share. As a group, sell-side analysts predict that ResMed Inc. will post 9.02 EPS for the current fiscal year.

ResMed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th were paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date was Thursday, August 15th. This is a boost from ResMed’s previous quarterly dividend of $0.48. ResMed’s dividend payout ratio (DPR) is 32.57%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.